Nov 7 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O:
AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS, ANNOUNCES STRATEGIC RESTRUCTURING TO SHARPEN FOCUS ON CONTINUED LUPKYNIS® GROWTH AND AUR200 DEVELOPMENT
AURINIA PHARMACEUTICALS INC - EXPECTS Q4 RESTRUCTURING CHARGE OF $15-$19 MILLION
AURINIA PHARMACEUTICALS INC - REITERATES 2024 NET PRODUCT REVENUE GUIDANCE OF $210-$220 MILLION
AURINIA PHARMACEUTICALS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 45% IN RESTRUCTURING
Source text: ID:nBw5JW1n2a
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.